HDAC9 and melanoma: For example, the usage of pan-HDAC inhibitor leads to the upregulated expression of PD-L1 and PD-L2 in melanoma, which can help to increase the treatment response to anti-PD-1 antibody and prolong the survival of preclinical mice (20).